Royalty Report: Diagnostic, Drugs, Biotechnology – Collection: 26289

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Diagnostic
  • Drugs
  • Biotechnology
  • Disease
  • Cancer
  • Diagnostic Substances
  • Medical
  • Therapeutic
  • Assay
  • DNA
  • ribonucleic acid
  • Food
  • Test/Monitoring
  • Pharmaceuticals
  • Surgical
  • Genome
  • Molecular
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26289

License Grant
The Licensor hereby grants to the Israeli Company, a non-exclusive, worldwide license to make, have made, market, distribute (directly or by means of local distributors), and Sell Licensed Products. Technology, generally characterized as Diagnostic Methods for Chlamydia Pneumoniae, Tech I.D. #07-86-34,  is covered by certain patent and know-how rights.
License Property
The Technology is comprised of three methods and associated materials for the detection and/or diagnosis of Chlamydia Pneumoniae, namely Monoclonal antibody-based antigen detection, serological antibody detection, and nucleic acid probe based detection.
Field of Use
“Field of Use”, as used herein, shall mean those portions of the Technology directly pertaining to methods and materials for the serological detection of antibodies, and their use by the Licensee to develop arid market assays.  The Field of Use expressly excludes the nucleic acid probe and Monoclonal antibody – based detection materials and methods of detecting Chlamydia Pneumoniae and expressly excludes the right to sell the diagnostic test results.

IPSCIO Record ID: 1150

License Grant
The Licensor granted an exclusive, worldwide license to the relevant Diagnostic Technology.

Diagnostic Technology  means any information, inventions, and discoveries made, conceived, derived, or otherwise reduced to practice by Licensor related to the Field.

License Property
U.S. Patent No. 5,516,638 Immunoassays for the Detection of Antibodies to Chlamydia Trachomatis in the Urine.
Field of Use
Field of Use means any urine-based medical diagnostic test.

IPSCIO Record ID: 2386

License Grant
The Licensor, an individual, and the Licensee desire to hereby amend and restate the Original Agreement in its entirety to clarify certain rights and obligations of the parties from and after March 1, 1997.
License Property
Licensor owns U.S. Patent No. 5,516,638 Immunoassays for the Detection of Antibodies to Chlamydia Trachomatis in the Urine.  Issued May 14, 1996.
Field of Use
The Field means any urine-based medical diagnostic test.

IPSCIO Record ID: 26453

License Grant
This Agreement, effective the University hereby grants to Company a worldwide, exclusive license with right to sublicense, to use Patent Rights and Know-How, to make, use, sell and have made Licensed Products, Licensed Combination Products, Licensed Processes, and Licensed Services in the Field of Use.  Sublicensees shall be subject to the terms and conditions of this Agreement.
License Property
University is the owner of their entire right, title and interest in the invention entitled 'Chlamydia Vaccine' which is the subject of three provisional United States Patent Applications, Serial Numbers 60/082,438; Licensed Combination Products shall mean any product that is comprised in part of a Licensed Product and in part of one or more other biologically active diagnostic, preventive or therapeutic agents which are not themselves Licensed Products (the Other Agents).

Chlamydia is an infection, a sexually transmitted disease.

Other Agents excludes diluents and vehicles of Licensed Products; vaccines for the prevention of disease caused by one or more of the following Chlamydia trachomatis, Chlamydia pneumonia, and Chlamydia psittaci; family of proteins involved in the formation of inclusion bodies which are crucial in the Chlamydia life cycle IncA, IncB, and IncC as well as TroA – April 13, 1998.

Field of Use
Field of Use shall mean all fields of use.

IPSCIO Record ID: 203391

License Grant
In furtherance of the settlement of the Lawsuit, Licensor is willing to license certain of its intellectual property to Licensee.

Licensor hereby grants to Licensee and its Affiliates a non-exclusive, royalty-bearing license to the Patent Rights, without the right to sublicense except as approved by Licensor in writing, to make, have made, use, sell and have sold Mab-based Licensed Products in the Territory, except products utilizing the format technology that is proprietary and that, as of today, is provided by Party A to Licensor in the test format in Licensor’s current Witness heartworm diagnostic products. For purposes of clarity, Licensor hereby acknowledges Licensee’s right to have such Mab-based Licensed Products or any component thereof manufactured by a third party. This license grant is limited only to Licensee’s own Mab-based Licensed Products whereas products which Licensee may distribute for other parties that may otherwise infringe the Patent Rights are specifically excluded, except as approved by Licensor in writing.

Licensor hereby also grants to Licensee and its Affiliates a non-exclusive, royalty-free license to the Patent Rights, without the right to sublicense except as approved by Licensor in writing, to make, have made, use, sell and have sold Di33-based Licensed Products in the Territory, except products utilizing the format technology that is proprietary and that, as of today, is provided by Party A to Licensor in the test format in Licensor’s current Witness heartworm diagnotic products. For purposes of clarity,  Licensor hereby acknowledges Licensee’s right to have such Di33-based Licensed Products or any component thereof manufactured by a third party. Furthermore, the Parties agree that, if a product qualifies as both a Mab-based Licensed Product and a Di33-based Licensed Product, it shall be subject to royalties. This license grant is limited only to Licensee’s own Di33-based Licensed Products whereas products which Licensee may distribute for other parties that may otherwise infringe the Patent Rights are specifically excluded, except as approved by Licensor in writing.

License Property
Patent Rights shall mean the ’631 Patent.  Licensor is the owner of United States Patent No. 4,789,631 issued on December 6, 1988, entitled “Immunoassay for Anti-Dirofilaria Immitis Antibody” (the ’631 Patent).

Licensed Products shall mean Mab-based Licensed Products and/or Di33-based Licensed Products.

Mab-based Licensed Products shall mean any heartworm antigen detection test product or part thereof having or using at least one monoclonal antibody that reacts with Dirofilaria immitis antigenic extract, including any said heartworm antigen detection test product or part thereof within the scope of a claim in the Patent Rights or manufactured by a process within the scope of a claim in the Patent Rights. For avoidance of doubt, the Parties agree that Licensees SOLO STEP® CH product and canine and feline reference laboratory heartworm antigen detection tests using such a monoclonal antibody are “Mab-based Licensed Products”.

Di33-based Licensed Products ” shall mean any heartworm antibody detection test product or part thereof using at least one recombinant Di33 protein, wherein a Di33 protein has properties as set forth in the ‘569 Patent, including any said heartworm antibody detection test product or part thereof within the scope of a claim in the Patent Rights or manufactured by a process within the scope of a claim in the Patent Rights.

Field of Use
This agreement pertains to health products for dogs, cats and horses relating to developing, manufacturing and marketing veterinary diagnostics, vaccines and other animal health related products worldwide.

IPSCIO Record ID: 27880

License Grant
The University grants to the Licensee an exclusive license under Regents' Patent Rights to make, have made, use, sell, offer to sell and import Licensed Products and to practice Licensed Methods.
License Property
Certain inventions, generally characterized as 'Detection of Carcinoma Metastases by Nucleic Acid Amplification' UC Case No. 91-145 (collectively the 'Invention')
Field of Use
Field of Use means diagnosis of metastases by nucleic acid amplification.  U.S. Patent Application Serial No. 07/720,061 entitled 'Detection of Carcinoma Metastases by Nucleic Acid Amplification'

IPSCIO Record ID: 144892

License Grant
Licensor grants a non-exclusive, non-transferable license under Patent Rights to practice Licensed Methods in the Field within Licensors laboratories and to make, have made, use, and export Licensed Products solely for use byLicensee, in the practice of Licensed Methods in the Field. License grant shall not include the right to sell Licensed Product and/or Licensed Method to third parties.
License Property
Licensor owns certain patents covering compositions and processes for detecting ribosomal nucleic acid subsequences belonging to groups of non-viral organisms.

The patents refer to Methods for Detection. Identification and Quantification of NonViral Organisms.

Field of Use
The Field shall mean the performance of human, clinical diagnostic Assays and Assay Series using one or more nucleic acid probes, including peptide nucleic acid probes and probes with modified sugar or phosphate groups, which are designed to detect whether or not bacteria are present in a sample by hybridizing to one or more pan-bacterial regions of ribosomal nucleic acid, whether ribosomal RNA or ribosomal DNA, in order to determine the presence or amount of bacteria which may be present in a human sample. 'Field' shall not include Assays and Assay Series only to detect, quantitate or identify any group of organisms less than or different than that encompassing all bacteria.

IPSCIO Record ID: 237259

License Grant
Licensor grants the Japanese Licensee, a non-exclusive, non-transferable license in the Territory under the Licensor Patent Rights to develop, make, have made, use, offer for sale, sell and have sold, Licensed Products in the Field, Future Licensed Products and to practice Licensed Methods in the Field.
License Property
The patents include Method for Detecting, Identifying and quantitating organisms and viruses, and, a Method for Determining  the sensitivity of Microorganisms, and, a Nucleic Acid Probe, and, Method for releasing RNA and DNA from Cells, and, Accelerated Nucleic Acid re-association method, and, Nucleic Acid Probes for Detection of non-viral organisms.

Licensor has developed proprietary technology relative to the performance of diagnostic assays based on genetic probe technology for the detection of agents causing infectious diseases, including viruses, and for the detection of cancer.

Licensor Patent Rights shall mean the Japanese patents, patent applications and international applications, to the extent they enter the national stage in Japan; all patents that have been issued or in the future issue, that are derived from or are related to, all patents to this Agreement, including without limitation utility model and design patents and certificates of invention.  

Licensed Product shall mean any already developed product or product in development as of the effective date of this agreement.  The products relate to DNA Probe – HBV Quantitative HBV, Infectious Disease , and Cancer.

Licensed Method shall mean any method, the use or practice of which would constitute, but for the license granted herein, an infringement of any issued Valid Claim within the Licensor Patent Rights.

Field of Use
Field shall mean the field of diagnostics, including but not limited to human, animal and environmental diagnostics and food testing and of investigational use only (IUO) applications.

The Field specifically does not include nucleic acid probe based testing of human blood, plasma or other blood products intended for direct transfusion or administration to humans. The Field also does not include nucleic acid probe based testing for infectious agents in blood in connection with organ transplants.  Excluded Assay Targets are Hepatitis Viruses, Herpes Viruses, HIV-1, HIV-2, HTLV-I, HTLV-11, MSRV,  and, HMMT-like Virus.

IPSCIO Record ID: 329692

License Grant
Prior to the Effective Date of this Agreement, the Parties have been involved in collaborative efforts to jointly develop assays for the ANAIS Instrumentation.

By this agreement, the Parties shall cooperate in the Development Transition and in the transfer of any information and Know-How necessary for Licensee to assume the development of the ANAIS Products.

Licensor grants a non-exclusive, non-transferable, worldwide license in the ANAIS Field to use the Licensor Technology to develop, make and have made, use, sell, offer for sale, have sold, and import the ANAIS Products, solely and exclusively for use on the ANAIS Instrumentation.

License Property
The ANAIS Instrument shall be an automated laboratory instrument for performing nucleic acid assays utilizing High Density DNA Probe Arrays.
Key BioChemistry Components include
– All enzymes used in transcription-based amplification for use in ANAIS Assays.
– All biochemical components used for amplification of amplicon of target with TMA, which is Licensors patents and technology relating to Nucleic Acid Sequence Amplification Methods.
– All probes, primers, and oligonucleotides used in ANAIS Assays.
– Nucleic acids used for ,positive and negative controls, standards, calibrators, and for quality control of ANAIS Assay components.

ANAIS products shall mean the following Probe Assays, in each case made, used, or sold under the license granted by Licensor and solely and exclusively for use on ANAIS Instrumentation
– Probe Assays for the detection, identification, quantification, and/or susceptibility testing for panels of microorganisms or agents (but specifically excluding single organisms) in specimens taken from humans, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken. A panel shall test for 10 or more distinct species of organisms or agents in the following groups of microorganisms
or agents  Bacteria; Viruses; Yeast/Fungi; or, Parasites.The panels shall be medically relevant.

– Probe Assays for the detection, identification, quantification, and/or susceptibility testing for an individual organism, drawn only from the groups or families listed below, in specimens taken from humans, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken Hepatitis virus; HIV virus; Herpes virus; Human papilloma virus; HTLV Virus; Yeast; Fungus; Parasite; and, Bacterium other than Neisseria gonorrhoeae or Chlamydia trachomatis.

– Probe Assays for testing of sequences encoding human leukocyte antigens in specimens taken from humans and/or

– Probe Assays to detect and /or precisely identify microorganisms or agents including bacteria, yeast, viruses and parasites for use in quality control processes of water, food products, and/or previously developed pharmaceutical or cosmetic products, and/or identify foods coming or derived from plants and/or/ animals for the purpose of confirming anticipated source(s) of the food.

Assay shall mean a diagnostic process or procedure applied to a sample, or a portion of a sample, whereby a particular chemical compound, or a collection of compounds, or a portion of a chemical compound, is detected and optionally quantified.

Field of Use
The ANAIS Field shall mean
– the detection, identification, quantification, and/or susceptibility testing of organisms or agents causing human clinical infectious diseases, as present in the human body, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken;
– testing for sequences encoding human leukocyte antigens;
– testing for microorganisms or agents, including bacteria, yeast, viruses and parasites in quality control processes of water, food products, and/or previously developed pharmaceutical or cosmetic products; and/or
– testing for the purposes of identifying genetically-modified foodstuffs or identifying animal species in foodstuffs.

The ANAIS Field specifically does not include testing for infectious agents in blood and blood products intended for transfusion, or the testing for infectious agents in blood in connection with organ transplants, or the testing of specimens from non-human animals or environmental sources except as specifically provided above, even if such testing is for the purpose of detecting or identifying organisms which are associated with infectious diseases in man.

IPSCIO Record ID: 28035

License Grant
The University or Licensor granted rights to certain patents and technology to the Ireland-based Licensee. The agreement is a royalty-bearing, non-exclusive license under Licensed Subject Matter to manufacture, have manufactured, use, distribute, Sell, offer to Sell, import, lease, loan or otherwise Commercialize Licensed Products in Licensee's ordinary course of business, within the Licensed Territory (worldwide) for use within Licensed Field. This Patent agreement is subsequent to a research agreement from which the relevant technology emerged.
License Property
The Licensed Subject Matter means protein and antibody based inventions. Patent Rights means the University's rights in information or discoveries covered by the University’s patent(s) or patent applications in the Licensed Territory for the following a.“VMP-Like Sequences of Pathogenic Borrelia”; and b.“VMP-Like Sequences of Pathogenic Borrelia Species and Strains”; and c.any patent(s) issuing from the foregoing applications; and d.any reissue, extension, revival or reexamination of the foregoing patent(s).
Field of Use
The Licensed Field means the use of Licensed Subject Matter to make, have made, use and Sell a protein or antibody-based human diagnostic test for Lyme disease.

IPSCIO Record ID: 29091

License Grant
In accordance with an agreement dated October 26, 1994 and amended in January 2003, between the Licensee and the Licensor, the Licensee has been granted a worldwide non-exclusive license to make, have made, market, distribute and sell products which use certain licensed rights or know-how relating to diagnostic methods for the detection of chlamydia pneumoniae in a defined field of use. In accordance with the agreement, the Licensee paid a license fee and undertook to pay, semi-annually, royalties as a percentage of net sales, and an annual license administration fee.

IPSCIO Record ID: 289170

License Grant
Licensor grants to the Swiss Licensee a worldwide, semi-exclusive license, without the right to sublicense, under the Licensor Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Field.

For the Licensor Transplantation Field License, Licensor grants a worldwide, non-exclusive license, without the right to sublicense, under  Licensoe Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Transplantation Field.

License Property
The patent rights relate to the human immunodeficiency virus (HIV).

Products means reagents, compositions or kits suitable for use in the Field or the Transplantation Field.

Field of Use
The Licensee intended application is for use in assays for the detection of nucleic acid sequences for use in in vitro diagnostics (excusing use in Blood Screening, but without limiting the effect of the Blood Screening Agreement.

Field means the commercial use of human in vitro diagnostic products that detect nucleic acid sequences of HIV. Expressly excluded from the Field are products in Blood Screening; and products specifically labeled or promoted for use in the Transplantation Field.

Transplantation Field means the commercial use of products that detect nucleic acid sequences for the screening of any biological materials intended for transfusion or transplantation, in each case from any donor, including autologous donors, other than the transfusion or transplantation of blood or its derivatives, components or replacements.

IPSCIO Record ID: 203305

License Grant
The Licensor of England grants to the Licensee a non-exclusive, non-sublicensable license within the Field and the Territory to use the Patents and the Know-How, to develop and have developed, make and have made, to Supply and have Supplied, either directly or through distributors, to import and have imported and to use and have used the Products within the Field.
License Property
The Scorpions technology is the means, methods and compositions used to detect nucleic acid amplification based on compositions that have one or more amplification primer portions linked to one or more nucleic acid probe portions and that are detectable as a result of the extension of one of the primers without concomitant amplification of the probe portion as described.

The products are any assay kit or other composition manufactured for use within the Field, the manufacture, use, sale, or import of which would, but for the license, infringe one or more valid claims of one or more of the issued Patents.

U.S.A. Patent 5,525,494 – Non-amplifiable Tails Patents

Scorpions(TM) probes are highly sensitive, sequence-specific, bi-functional molecules containing a PCR primer covalently linked to a probe. Scorpions probes provide strong fluorescent signals, excellent sequence discrimination, short reaction times, and predictable probe design. The interaction of the probe and the desired target occurs very rapidly and in advance of any competing side reactions such as the formation of internal secondary structures or re-annealing. The unique intra-molecular nature of the Scorpions reaction means that it is ideally suited for fast, quantitative, real-time PCR analysis.

Field of Use
This agreement is for the human in vitro diagnostics field.

Scorpions(TM) technology will provide benefits in speed and in developing highly multiplexed tests.  The first commercial products expected to use the Scorpions probes for Licensee will be in the recreational water testing area.

IPSCIO Record ID: 27510

License Grant
The Licensor gave an exclusively license to the Company of patent titled One-Step In Situ Hybridization Assay.
License Property
The patent applications owned or co-owned by the Company either seek to cover improvements in reagents and methods of performing an in situ hybridization process or seek to cover methods of identifying and isolating fetal cells for prenatal diagnosis by in situ hybridization.

Among its claims is one that recites a method for assaying nucleic acids in a sample of cells having substantially intact membranes. The claimed method consists essentially of the steps of contacting the sample with a medium comprising a fixative agent, a denaturing agent, a hybrid stabilizing agent, a buffering agent, a membrane pore-forming agent and at least one nucleic acid probe. The contacting is under hybridizing conditions. The sample is incubated with the medium in the presence of at least one detectable label, and duplex formation is detected by means of the label, wherein the method is capable of detecting as few as one to five copies of a target nucleic acid per cell. Another claim applies to the foregoing process, in which the detection is carried out by flow cytometry. The patent also contains claims for kits.

IPSCIO Record ID: 324838

License Grant
Licensor, a cancer treatment and research institution, grants an exclusive option to take an exclusive world-wide License under Licensed Patents and Technology.

Upon exercise of its option rights, Licensee shall have the exclusive rights in the Territory, with the right to grant sublicenses, to make, have made, use and sell, licensed products utilizing the Licensed Patents and Technology and products utilizing Licensed Technology.

License Property
The patent is titled Prostate-Specific Membrane Antigen.

Gene technology means that part of Licensed technology that pertains to any DNA encoding the prostate specific membrane (PSM) antigen or any portion of the PSM antigen and any DNA, cDNA, and other derivative or portion of said gene that expresses the PSM antigen, including, but not limited to, diagnostic methods employing DNA probes or PCR techniques to detect prostate cancer and gene therapy applications.

Know-how means the skill or ingenuity based upon the body of knowledge and data which comprise all of the methods, processes, designs, engineering information, trade secrets, and other information and data relating to prostate specific membrane (PSM) antigen recognized by the monoclonal antibody Licensees-356, any subunits of such antigen, any other monoclonal antibodies or binding proteins or peptides recognizing such antigen and any gene or gene segment encoding for such antigen or portion of such antigen, Confidential information and Gene technology which Licensor develops, employs in its own activities, or has available for use prior to or during the term of this Agreement.

Licensed technology means information and data relating to prostate specific membrane (PSM) antigen recognized by the monoclonal antibody Licensees -356, any subunits of such antigen, any other monoclonal antibodies or binding proteins or peptides recognizing such antigen and any gene or gene segment encoding for such antigen or portion of such antigen owned by Licensor as of the effective date or acquired during the term of this agreement; including without limitations, inventions, biological materials, computer programs, technical data, apparatus and Know-how, Gene technology and confidential information, whether patentable or unpatentable.

Licensees-356 is a prostate cancer monoclonal antibody conjugate.

Field of Use
The agreement relates to the detection of prostate cancer and gene therapy applications.

The Parties have a development program involving the prostate specific membrane antigen (PSM) and Licensees prostate cancer monoclonal antibody conjugate, -356.

IPSCIO Record ID: 26464

License Grant
The Licensee was granted the non-exclusive right to polymerase chain reaction technology or 'PCR' to perform the Licensed Services within the United States and its possessions and the Commonwealth of Puerto Rico.

The Licensed Services shall mean the performance of an Assay by BTRL to detect nucleic acid sequences associated with a human disease or condition within the Licensed Field.  Licensed Services include but are not limited to, any combination of the steps of collecting a sample for analysis, isolating nucleic acid sequences therein, amplifying one or more desired sequences, analyzing the amplified material and reporting the results.

License Property
PCR Technology shall mean polymerase chain reaction technology covered by United States Patent Nos. B1 4,683,195 and B1 4,683,202.
Field of Use
The Licensed Field shall mean the field of human in vitro diagnostics solely for the detection of genetic diseases, genetic pre-disposition to disease, microorganisms associated with infectious diseases, cancer, or for tissue transplant typing or Parentage.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.